国际标准期刊号: 2155-952X

生物技术与生物材料

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • 打开 J 门
  • Genamics 期刊搜索
  • 学术钥匙
  • 研究圣经
  • 中国知网(CNKI)
  • 访问全球在线农业研究 (AGORA)
  • 电子期刊图书馆
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • SWB 在线目录
  • 虚拟生物学图书馆 (vifabio)
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Biomaterials 2020: Actinobacterial Reduction of Nano Graphene Oxide for Biomedical Applications

Kavitha and R. Balagurunathan

Graphene oxide (GO) reduction, in particularly, the simple, cost effective and environmental benign microbial method attracts high over the other methods. Extracellular mediated actinobacterial reduction of nano graphene oxide is focused for the high purity and productivity of the product without any toxicity. In addition, Indian plant Cynodon dactylon also have an excellent ability to reduce the GO. Reduction of the nano-graphene oxide (nGO) to graphene nanoparticles (nRGO) was identified by visual colour change from brown to black. Further, the reduction of nGO into nRGO was confirmed through XRD pattern. Fig. 1 shows the disappearance of the peak at 2θ = 10° in the GO and formation of new broad peak at 2θ = 26° (JCPDS no. 411487) supports that the GO is completely reduced into graphene. The average Crystallite size of rGO is 8-10nm (Scherrer’s equation).  Further the bioactivity of biological reduced nano graphene give the superior results compare than the chemically synthesized particles. Appropriate degradation as well as HAp layer formation supports the biological synthesis and suggests for the fruitful outcome for therapeutical applications. Microorganism has ability to produce secondary metabolites, which have found application in  combating a variety of human infections. Among the microorganisms, marine bacteria particularly actinomycetes produce unique and novel secondary metabolites and it is useful for different biological activities, such as antifungal, antibacterial, antitumor, anticancer, anti-parasitic and immunosuppressive activities. Soil dwelling, actionbacteria are more potent source of novel enzymes and secondary metabolites, including many antibiotics and bioactive compounds than the other microorganism. Nearly 80% of naturally occurring antibiotics have been isolated from different actinomycetes especially from Streptomycetes. Streptomycetes yielded many therapeutic agents such as streptomycin, erythromycin, tetracycline, amphotericin, chloramphenicol, daptomycin fosfomycin, lincomycin, neomycin, puromycin, anticancer drugs exemplified by adriamycin and the immunosuppressant tacrolimus. There are more bioactive

compounds such as avermectin (Streptomyces avermitilis), bleomycin (Streptomyces verticillus) and daunomycin (Streptomyces peuceticus) as antitumor compounds, Tacrolimus, is an binding protein formerly known as FK506 or fujimycin (Streptomyces tsukubaensis) as an immunosuppressant, and validamycin (Stereptomyces hygroscopicus var. limoneus) as a treatment of rice sheath blight disease. Methicillin- resistant Staphylococcus aureus (MRSA) is a pathogen responsible for a wide range of infections such as boils, pneumonia, osteomyelitis, endocarditis, bacteremia, etc. and has developed resistance to the majority of conventional antibiotics. Similarly, Enterococcus infections are caused mostly by vancomycin resistant Enterococcus faecalis and E.coli (VRE). Clinical pathogens such as Staphylococcus aureus, Pseudomonas, and Enterobacteriaceae, Candida albicans, C. glabrata and Cryptococcus neoformans plays vital role in many degenerative diseases. Similarly, Candida species such as C. albicans, C. glabrata and Cryptococcus neoformans cause arthritis, infections in immune suppressed individuals and infections with bone rupture and cause degenerative diseases. Pathogens often transform their genomic alignment against existing antibiotics and loss their sensitivity and became a drug resistant pathogens. The number of drug resistant pathogens are increasing day by day and become serious public health problems. In addition, recent years new therapeutic agents have entered in the clinical area, unfortunately with some side effects. Compare than the graphene oxide, reduced graphene oxide facilitates incredible properties such as high surface area, bacterial inhibition, enhanced mechanical property, bioactive nature. Especially, nano-graphene possess unique reinforcing behaviour with a large surface area plays a key role in osteoinduction and osteoconduction which promotes cell adherence. Hence, grapheme is used for orthopaedic and bone regeneration application vitally. In addition, the cancer cell targeting and diagnosis through graphene attract us more towards the biomedical application. The most commonly used chemical reducing agents for graphene oxide are anhydroushydrazine, hydrazine monohydrate, sodium borohydride, and hydroquinone. These reducingagents are highly toxic and harmful. Moreover, hydrazine-reduced graphene tends to agglomerate irreversibly and converts into graphite. Metal/hydrochloric acid reduction is another alternative; however, an impurity formed from the residual metal hinders further applications. Therefore, search towards the environmental friendly, green production of graphene is increased. Especially, microbial mediated syntheses are focused for owing to its simplicity, nill-toxicity, stability,viability, and scalability.